Respironics completes acquisition of Stimotron
This article was originally published in Clinica
Executive Summary
Respironics has completed the purchase of its German distributor, Stimotron Medizinische Gerate, for $10.25 million, plus additional payments of up to $3.75 million over the next four years. Stimotron, which is based in Wendelstein, markets therapy systems for the treatment of obstructive sleep apnoea.